U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07546552) titled 'Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis' on March 26.
Brief Summary: Female infertility presents a significant societal challenge that will be aggravated in the future due to delayed parenthood. Our translational research suggests that receptor activator of NF-κB ligand (RANKL) is a novel treatment target, during assisted reproductive techniques and that inhibition of this pathway may reduce the impact of aging on the ovary. RANKL is a regulator of bone health, and an antibody (denosumab) blocking RANKL activity is used clinically to treat osteoporosis. Previously, we have shown that inhibition ...